Vitrolife AB (publ) – Interim report Q3, 2025: Strong growth in Americas

GOTHENBURG, Sweden, Oct. 23, 2025 /PRNewswire/ —

Third quarter

• Sales of SEK 835 (867) million, 3% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -7%. Organic growth in local currencies excluding discontinued business* was 5%.
• Sales per region, in local currencies, were -2% in EMEA, +4% excluding discontinued business, +11% in Americas and +1% in APAC.
• Sales per product group, in local currencies excluding discontinued business, were +7 in Consumables, +8% in Technologies and +3% in Genetics.
• Sales per product group, in local currencies, were +4% in Consumables, +8% in Technologies and 0% in Genetics.
• Gross margin increased to 58.9% (58.6), explained by a favourable product mix despite negative currency impact.
• Earnings before depreciation and amortisation (EBITDA) amounted to SEK 253 (289) million, resulting in an EBITDA margin of 30.3% (33.4), impacted by negative currency effect.
• Operating cash flow amounted to SEK 255 (206) million.
• Net income amounted to SEK 102 (116) million, resulting in earnings per share of SEK 0.75 (0.85).

First nine months

• Sales of SEK 2,548 (2,650) million, 1% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -5%. Organic growth in local currencies excluding discontinued business was 4%.
• Sales per region, in local currencies, were +1% in EMEA, +8% excluding discontinued business, +8% in Americas and -5% in APAC.
• Sales per product group, in local currencies excluding discontinued business, were +7% in Consumables, -1% in Technologies and +3% in Genetics.
• Sales per product group, in local currencies, were +4% in Consumables, -2% in Technologies and +1% in Genetics.
• Gross margin decreased to 58.1% (58.6) negatively impacted by currency.
• Earnings before depreciation and amortisation (EBITDA) amounted to SEK 753 (888) million, resulting in an EBITDA margin of 29.5% (33.5), significantly impacted by negative currency effect.
• Operating cash flow amounted to SEK 475 (640) million.
• Net income amounted to SEK 301 (375) million, resulting in earnings per share of SEK 2.23 (2.76).

Gothenburg, October 23, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor,
CEO

* Discontinued business refers to discontinued activities in certain markets in EMEA.

The information was submitted for publication, through the agency of the contact persons set out above, at 23-10-2025 08:00 CET.

Contact:

Amelie Wilson, Investor relations, external corporate communications and executive support, awilson@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/vitrolife-ab–publ-/r/interim-report-q3–2025–strong-growth-in-americas,c4254622

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ—interim-report-q3-2025-strong-growth-in-americas-302592532.html

SOURCE Vitrolife AB (publ)